Leqembi is the first Alzheimer's treatment that alters the disease's course by removing toxic beta amyloid protein from the brain. Eisai plans to offer partial drug cost coverage in collaboration with a Chinese medical insurance company. China approved the treatment in January following US FDA approval in July.